Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin (Q37087348)

18 August 2017

title

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin (English)

1 reference

18 August 2017

13

David Veenstra

1 reference

18 August 2017

David A Flockhart

1

1 reference

18 August 2017

Dennis O'Kane

2

1 reference

18 August 2017

Marc S Williams

3

1 reference

18 August 2017

Michael S Watson

4

1 reference

18 August 2017

David A Flockhart

5

1 reference

18 August 2017

Brian Gage

6

1 reference

18 August 2017

Roy Gandolfi

7

1 reference

18 August 2017

Richard King

8

1 reference

18 August 2017

Elaine Lyon

9

1 reference

18 August 2017

Robert Nussbaum

10

1 reference

18 August 2017

Dennis O'Kane

11

1 reference

18 August 2017

Kevin Schulman

12

1 reference

18 August 2017

Marc S Williams

14

1 reference

18 August 2017

Michael S Watson

15

1 reference

18 August 2017

ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use

16

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

10

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

139-150

1 reference

https://scigraph.springernature.com/pub.10.1097/gim.0b013e318163c35f

18 August 2017

exact match

0 references

cites work

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Rapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Importance of device evaluation for point-of-care prothrombin time international normalized ratio testing programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E318163C35F

10.1097/GIM.0B013E318163C35F

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference